Abrogation of cisplatin-induced nephrotoxicity in mice by alpha lipoic acid through ameliorating oxidative stress and enhancing gene expression of antioxidant enzymes

• Published in: European journal of pharmacology Vol. 668; no. 1-2; pp. 278 - 284
• Main Authors: El-Beshbishy, Hesham A., Bahashwan, Saleh A., Aly, Hamdy A.A., Fakher, Hesham A.
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier B.V 01.10.2011; Elsevier
• Subjects: Alpha lipoic acid; Animals; Antineoplastic Agents - adverse effects; antioxidants; Antioxidants - metabolism; Biological and medical sciences; blood serum; body weight; Body Weight - drug effects; catalase; Cisplatin; Cisplatin - adverse effects; creatinine; Cytoprotection - drug effects; gene expression; Gene Expression Regulation, Enzymologic - drug effects; genes; glutathione; glutathione peroxidase; Inducible nitric oxide synthase; Kidney - drug effects; Kidney - enzymology; Kidney - metabolism; Kidney - pathology; kidneys; lipoic acid; Male; malondialdehyde; Medical sciences; messenger RNA; Mice; Nephrotoxicity; Nitric oxide; Nitric Oxide - metabolism; Organ Size - drug effects; oxidative stress; Oxidative Stress - drug effects; Pharmacology. Drug treatments; poisoning; RNA, Messenger - genetics; RNA, Messenger - metabolism; superoxide dismutase; Thioctic Acid - pharmacology; urea; Alpha lipoic acid; Nephrotoxicity; Nitric oxide; Inducible nitric oxide synthase; Cisplatin; Antineoplastic agent; Lipoic acid; Oxidative stress; Urinary system disease; Enzyme; Toxicity; Rodentia; Antioxidant; Gene expression; Nitric-oxide synthase; Kidney; Alkylating agent; Vertebrata; Mammalia; Urinary system; Mouse; Animal; Oxidoreductases; Platinum II Complexes
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/j.ejphar.2011.06.051

Cisplatin is chemotherapeutic drug used in treatment of malignancies. However, its clinical utility is limited by nephrotoxicity. The purpose of present study is to investigate biochemical and molecular effects of alpha lipoic acid (ALA) to protect against cisplatin-induced nephrotoxicity in mice. Cisplatin (12mg/kg/day) was administered i.p. for 4days. Group of mice were given ALA (20mg/kg/day) for 18days. Another set were administered ALA for 4days before and 14days after cisplatin intoxication. The results obtained revealed that kidney/body weight ratio of cisplatin-treated mice was increased by +40%. ALA intake declined the ratio by −19%. Serum creatinine and urea levels were increased in cisplatin-treated mice by +375% and +69%, respectively. These changes were moved to normalcy upon ALA intake. Cisplatin treatment elevated malondialdehyde (MDA) by 27 fold and declined reduced glutathione (GSH) by −49%. Cisplatin decreased catalase, superoxide dismutase (SOD) and glutathione peroxidase (GPx) enzymes by −47%, −49% and −59%, respectively. ALA decreased the MDA by −286% and increased the GSH, catalase, SOD and GPx levels by +60%, +81%, +90% and +38%, respectively. ALA increased mRNA expression of catalase, CuZn SOD and GPx genes near to normalcy compared to cisplatin-treated mice. Cisplatin-treated mice increased caspase-3-activity by +223%, nitric oxide (NO) by +74% and inducible nitric oxide synthase (iNOS) by 10 fold. ALA intake declined these changes by −43%, −45% and −73%, respectively. ALA may play renoprotective role on cisplatin-induced nephrotoxicity through antioxidant and antiapoptotic mechanisms combined with initiation of mRNA expression of antioxidant genes.